Biogen reports British Columbia to Reimburse TECFIDERA Biogen Idec Canada announced that TECFIDERA is now available for reimbursement in British Columbia through B.C. PharmaCare. Effective June 24, TECFIDERA is now eligible for reimbursement as a first-line monotherapy for people diagnosed with RRMS according to the current McDonald clinical criteria and magnetic resonance imaging evidence, when prescribed by a neurologist from a designated MS clinic, who meet the following criteria: is 18 years of age or older; meet the Limited Coverage criteria; has had at least two disabling attacks of MS in the previous two years; and is ambulatory with or without aid with an Expanded Disability Status Scale score of 6.5 or less. TECFIDERA is also available as a second-line monotherapy for a change of therapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have experienced failure or intolerance to a previous disease-modifying therapy.
Biogen price target lowered to $400 from $425 at Credit Suisse Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.